Status:
RECRUITING
Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborating Sponsors:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions:
Pancreatic Cancer
Chronic Pancreatitis
Eligibility:
All Genders
30-84 years
Brief Summary
The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer will be responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characte...
Detailed Description
Objectives: 1. Evaluate the pancreatic polypeptide response following a standardized mixed meal in new onset diabetes associated with PDAC (particularly with a proximal tumor) and chronic pancreatiti...
Eligibility Criteria
Inclusion
- All Participants must sign an informed consent indicating that they are aware of the investigational nature of this study. Participants must have signed an authorization for the release of their protected health information.
- Participants must be ages ≥30 and \<85.
- Participants must have a diagnosis of one of the following based on study definitions;
- New Onset Diabetes (\<3 years) in participants with Pancreatic Cancer (PDAC);
- New Onset Diabetes (\<3 years) in participants with Chronic Pancreatitis;
- New Onset Diabetes (\<3 years) in participants without Pancreatic disease (i.e., T2DM)
- Long standing T2DM (≥3 years) without Pancreatic disease
- Long standing diabetes (≥3 years) in participants with PDAC
- Long standing diabetes (≥3 years) participants with chronic pancreatitis
- non-diabetic participants with PDAC
- non-diabetic participants with chronic pancreatitis
- non-diabetic controls without Pancreatic disease
Exclusion
- Participants must not have any significant medical illnesses (including diabetes) that in the investigator's opinion cannot be adequately controlled with appropriate therapy or would compromise the Participant's ability to tolerate study interventions.
- Diabetes not stable enough to permit holding of diabetes medications in Participants undergoing mixed meal tolerance testing.
- Participants taking higher doses of insulin (≥0.75 unit/kg/day). \[Criterion is not applicable for PDAC Participants undergoing fasting only blood collection\]
- Participants in the non-pancreatic disease subgroup on longer acting agents, including thiazolidinediones and once-weekly GLP-1 agonists (Bydureon \[exenatide\], Ozempic \[semaglutide\], Trulicity \[dulaglutide\]). \[Criterion is not applicable for Participants in the CP and PDAC groups\].
- Participants currently receiving oral steroid medications.
- Hospitalization for acute pancreatitis within 2 months before study visit. \[Criterion is not applicable for PDAC Participants undergoing fasting only blood collection\]
- The presence of a symptomatic cyst in Participants with CP. \[Criterion is not applicable for PDAC Participants undergoing fasting only blood collection; this includes cancer arising from a mucinous cystic lesion\].
- Any Participant with a known pancreatic cancer histologic subtype other than adenocarcinoma (e.g., Participants with pancreatic neuroendocrine tumors are excluded).
- Previous pancreatic surgery (including total pancreatectomy, pancreaticoduodenectomy, distal pancreatectomy, pancreaticojejunostomy, enucleation, or Frey procedure). \[Criterion is not applicable for CP Participants with diabetes who have a history of pancreaticoduodenectomy, pancreaticojejunostomy, distal pancreatectomy, or Frey\].
- Previous treatment for pancreatic cancer, including chemotherapy or radiation.
- Previous vagotomy or gastric surgery, including endoscopic gastric reduction procedures. \[Criterion is not applicable for PDAC Participants undergoing fasting only blood collection\].
- Previous diagnosis of gastroparesis. \[Criterion is not applicable for PDAC Participants undergoing fasting only blood collection\].
- Participants on treatment for any cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix).
- Allergy or intolerance to ingredients in Boost drink in Participants undergoing mixed meal testing (see Appendix 13.9) \[Criterion is not applicable for PDAC Participants undergoing fasting only blood collection\].
Key Trial Info
Start Date :
April 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2027
Estimated Enrollment :
775 Patients enrolled
Trial Details
Trial ID
NCT03460769
Start Date
April 1 2021
End Date
June 30 2027
Last Update
November 25 2025
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048
2
Stanford University
Stanford, California, United States, 94305
3
University of Florida
Gainesville, Florida, United States, 32610
4
Indiana University
Carmel, Indiana, United States, 46280